Surrogate endpoints in clinical trials: cancer.

By S. Ellenberg, J. Hamilton. 1989

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Some Thoughts Concerning Transfer Learning, with Applications to Meta-analysis and Data-sharing Estimation (2012, background): “In the words of Ellenberg and Hamilton (1989) “investigators use surrogate endpoints when the endpoint of interest (e.g., life expectancy or survival) is too diﬃcult and/or expensive to measure routinely and when they can deﬁne some other, more readily measurable, endpoint (a biological marker),…”
The validation of surrogate endpoints in meta-analyses of randomized experiments. (2000, background): “Surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the endpoints of interest, which are referred to as the ‘true’ or ‘final’ endpoints (Ellenberg and Hamilton, 1989).”
Transportability across studies: A formal approach (2011, methodology): “In the words of Ellenberg and Hamilton (1989) “investigators use surrogate end-points when the endpoint of interest is too diﬃcult and/or expensive to measure routinely and when they can deﬁne some other, more readily measurable, endpoint, which is suﬃ-ciently well correlated with the ﬁrst to…”
On the use of surrogate end points in randomized trials (2000, background): “In an in ̄uential series of papers published in 1989, various researchers commented on the issues involved in using surrogate end points in cancer (Ellenberg and Hamilton, 1989), cardiovascular diseases (Wittes et al.”